← Back to Search

HIIT Exercise for Endometrial Cancer

N/A
Waitlist Available
Led By Victoria Bae-Jump, MD
Research Sponsored by UNC Lineberger Comprehensive Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients with a diagnosis of endometrial cancer who are to undergo hysterectomy and staging
Endometrioid histology endometrial cancer
Must not have
Severely impaired hearing or speech
Inability to speak English
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 years
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing whether high-intensity interval training (HIIT) can help fight endometrial cancer.

Who is the study for?
Women aged 40-75 with endometrial cancer, scheduled for surgery, and a BMI of 30-50 kg/m2 can join. They must have early-stage disease, access to email and a smartphone, and be able to visit the lab for tests. Those with recent severe cardiovascular events, other interventions or conditions that limit safe participation are excluded.
What is being tested?
The trial studies the effects of high intensity interval training (HIIT) on women with endometrial cancer before their standard surgery. It aims to see if HIIT has anti-cancer benefits by examining changes in tissue and blood markers.
What are the potential side effects?
While not drug-related, side effects from HIIT may include muscle soreness, fatigue, increased heart rate during exercise, risk of injury if not performed correctly, and possible exacerbation of pre-existing health conditions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have endometrial cancer and am scheduled for a hysterectomy and staging.
Select...
My cancer is a type of endometrial cancer called endometrioid.
Select...
I am between 40 and 75 years old.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have severe hearing or speech impairments.
Select...
I cannot speak English.
Select...
I have not been hospitalized for stroke, heart attack, or heart failure, nor had surgery for blocked arteries in the last 3 months.
Select...
I have severe dementia or significant memory loss.
Select...
I use insulin to manage my diabetes.
Select...
I have a condition that limits my physical activity.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in proliferative markers in endometrium before and after HIIT exercises

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: HIIT exerciseExperimental Treatment1 Intervention
Participants will perform HIIT exercises as instructed by the study team in the weeks prior to standard of care surgery

Find a Location

Who is running the clinical trial?

UNC Lineberger Comprehensive Cancer CenterLead Sponsor
364 Previous Clinical Trials
92,352 Total Patients Enrolled
8 Trials studying Endometrial Cancer
211 Patients Enrolled for Endometrial Cancer
National Cancer Institute (NCI)NIH
13,938 Previous Clinical Trials
41,023,138 Total Patients Enrolled
73 Trials studying Endometrial Cancer
73,262 Patients Enrolled for Endometrial Cancer
Victoria Bae-Jump, MDPrincipal InvestigatorUniversity of North Carolina, Chapel Hill
1 Previous Clinical Trials
3 Total Patients Enrolled
1 Trials studying Endometrial Cancer
3 Patients Enrolled for Endometrial Cancer

Media Library

HIIT exercise Clinical Trial Eligibility Overview. Trial Name: NCT04025229 — N/A
Endometrial Cancer Research Study Groups: HIIT exercise
Endometrial Cancer Clinical Trial 2023: HIIT exercise Highlights & Side Effects. Trial Name: NCT04025229 — N/A
HIIT exercise 2023 Treatment Timeline for Medical Study. Trial Name: NCT04025229 — N/A
~3 spots leftby Sep 2025